Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075464 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01075464 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 64 participants.
The verdict
NCT01075464, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
Interventions
- DRUG bevacizumab
- DRUG paclitaxel
- DRUG MEGF0444A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01075464
The ClinicalTrials.gov registry entry for NCT01075464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT01075464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01075464 about?
NCT01075464 is a clinical study titled "A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors". This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
What is the current status of trial NCT01075464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2010-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01075464?
The interventions under investigation include: bevacizumab (DRUG), paclitaxel (DRUG), MEGF0444A (DRUG).
Who is sponsoring clinical trial NCT01075464?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.